RxDoctor Payments Data

Craig Grossman, MD

Pulmonary Disease · Abington, PANPI 1528301751

Payments from drug & device makers

$304in general payments, 2019–2025

Across 13 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$78
  • GSK$59
  • AstraZeneca$46
  • United Therapeutics Corporation$25
  • Mylan Specialty L.p.$25
  • Merck$24
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$304 in reported general payments places this provider in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$138,259
Medicare patients
411
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol53$30,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$29,811
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$22,039
Spiriva RespimatTiotropium Bromide30$15,487
Spiriva HandihalerTiotropium Bromide13$12,790
Incruse ElliptaUmeclidinium Bromide28$11,539
DuleraMometasone/Formoterol13$6,107
Arnuity ElliptaFluticasone Furoate25$5,056
Qvar RedihalerBeclomethasone Dipropionate17$3,727
SymbicortBudesonide/Formoterol Fumarate13$3,345
Albuterol Sulfate HfaAlbuterol Sulfate122$3,276
Ventolin HfaAlbuterol Sulfate18$953
Montelukast Sodium68$402
Fluticasone Propionate33$382
Prednisone34$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$59$98,639173 claims
MerckDulera$24$6,10713 claims
AstraZenecaSymbicort$46$3,34513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →